Company news

Neuren Pharmaceuticals Limited news in 2016

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2016, newest first.

View company

Notice of special meeting of shareholders

November 13, 2016

Neuren completes enrolment in Rett syndrome Phase 2 trial

November 13, 2016

Neuren receives $0.9m from exercise of last expiring options

October 27, 2016

Neuren expands Phase 2 Rett syndrome pediatric trial

August 24, 2016

Neuren presents at Rettsyndrome.org 2016 Research Symposium

June 24, 2016

Grant of new patent for Autism Spectrum Disorders

June 22, 2016

Results of Phase 2 trial in moderate to severe TBI

April 25, 2016

First subject commences Neurens Rett syndrome Phase 2 trial

April 7, 2016

Neuren awarded Rett Syndrome trial grant

March 30, 2016

Trial of Second Neuren Drug Motiva to be Initiated

March 30, 2016

Neuren Starts Phase II Trial of NNZ2566

March 30, 2016

Grant funding for TFF oncology program

March 30, 2016

Cato strategic partnership and appoints US CMO

March 30, 2016

Neuren Initiates NNZ2566 Oral Formulation Development

March 30, 2016

Neuren Completes Additional Phase I Study for TBI

March 30, 2016

Neuren reduces outstanding convertible note principal

March 30, 2016

Neuren Completes Phase II trial Cohort 1

March 30, 2016

Neuren Rights Issue Offer Document (NZ residents)

March 30, 2016

Neuren Rights Issue Letter of Offer (Australian residents)

March 30, 2016

NEU: Neuren places $3m of rights issue shortfall

March 30, 2016

Rett Syndrome pre-IND meeting held with FDA

March 30, 2016

Neuren to proceed with oral NNZ2566 trial

March 30, 2016

Neuren Completes Phase II trial Cohort 2

March 30, 2016

Neuren 2011 Preliminary Final Report

March 30, 2016

Appendix 4E and Financial Report 31 December 2015

February 24, 2016

Trofinetide successful in Phase 2 trial in Fragile X

February 11, 2016

US$3m increase to US Army grant and INTREPID outlook update

February 10, 2016

Share Purchase Plan offer documents

February 10, 2016

Shareholder Update

February 10, 2016

Shareholders provide further support for Rett syndrome

February 10, 2016

Results in Fragile X Model with NNZ 2591

February 10, 2016

Response to social media commentary re Rett trial

February 10, 2016

Response to ASX Price Query Letter

February 10, 2016

Preliminary Final Report and audited Financial Statements

February 10, 2016

Preliminary Final Report and 2014 full year accounts

February 10, 2016

Placement of $21.5m to accelerate execution of strategy

February 10, 2016

Orphan drug designation from FDA for NNZ-2566 in Fragile X

February 10, 2016

New US patent covering use of trofinetide for Rett syndrome

February 10, 2016

Neuren TAP Conference presentation and Fragile X results

February 10, 2016

Neuren successful in Rett syndrome Phase 2 trial

February 10, 2016

Neuren submits Orphan Drug/Breakthrough Therapy applications

February 10, 2016

Neuren`s Perseis selects lead antibodies

February 10, 2016

Neuren reports progress in orphan drug programs

February 10, 2016

Neuren reports progress in NNZ-2566 clinical trial programs

February 10, 2016

Neuren receives two new patents

February 10, 2016

Neuren receives response to request for Breakthrough Therapy

February 10, 2016

Neuren receives new US patent for NNZ-2591

February 10, 2016

Neuren receives Fast Track designation for Fragile X

February 10, 2016

Neuren receives ethics approval to start Concussion trial

February 10, 2016

Neuren opens new IND for NNZ-2566 in Fragile X Syndrome

February 10, 2016

Older news releases →

Decks in 2016